Target intelligence / Profile preview

Severe acute respiratory syndrome coronavirus 2 virion surface (SARS-CoV-2 virion surface)

Target
SARS-CoV-2 virion surface
Molecular classification
Viral surface protein complex, Enveloped virus surface, Glycoprotein
01

Overview

The intact SARS-CoV-2 virion surface is the primary interface between the virus and the host, composed of a host-derived lipid bilayer embedded with structural proteins [V'kovski et al., 2021]. The Spike (S) glycoprotein is the most critical component, as it mediates binding to the host receptor Angiotensin-Converting Enzyme 2 (ACE2) and facilitates viral entry via membrane fusion [Hoffmann et al., 2020]. Other structural proteins on the surface include the Membrane (M) protein, which provides structural integrity, and the Envelope (E) protein, which is involved in viral assembly and budding [Schoeman & Fielding, 2019]. This surface is the main target for the host immune response, specifically for neutralizing antibodies that block the Spike protein's interaction with ACE2 [Kyriakidis et al., 2021]. Therapeutic interventions targeting the virion surface include monoclonal antibodies and vaccines designed to elicit a robust anti-Spike response [Hansen et al., 2020]. Additionally, the lipid envelope is susceptible to physical disruption by virucidal agents such as alcohols and detergents [Kampf et al., 2020]. Understanding the structural dynamics of the virion surface is essential for developing effective countermeasures against COVID-19 and monitoring the impact of emerging variants [V'kovski et al., 2021].

Other names
SARS-CoV-2 viral envelopeSARS-CoV-2 surface proteinsCOVID-19 virus surfaceSARS-CoV-2 virion
02

Mechanism of action

Neutralization of viral entry by binding to surface proteins (primarily Spike) to prevent ACE2 interaction or membrane fusion; physical disruption of the viral envelope [Hansen et al., 2020; Kampf et al., 2020].

03

Biological functions

Viral attachmentMembrane fusionViral entryImmune response
04

Disease associations

InfectionCOVID-19
05

Safety considerations

Viral evolution and antigenic escapeAntibody-dependent enhancement (ADE)Hypersensitivity reactionsVaccine-associated enhanced respiratory disease (VAERD)
06

Interacting drugs

Sotrovimab

11 more in the full profile.

07

Biomarkers

Anti-SARS-CoV-2 Spike protein antibodiesSARS-CoV-2 S1 antigenViral RNA load

Beyond the preview

Go deeper on Severe acute respiratory syndrome coronavirus 2 virion surface (SARS-CoV-2 virion surface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Severe acute respiratory syndrome coronavirus 2 virion surface (SARS-CoV-2 virion surface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call